The EMBRACE study of CYB003 will now run across Ireland, Poland, Greece, and the U.K.
FLHLF wins first-ever EU approval for compassionate use of its botanical psilocybin drug, PEX010, in Germany.
CMND's CMND-100 enters Phase I/IIa testing at TASMC, aiming to tackle alcohol use disorder without the trip.
CPO Dr. Guy Levine tells The Fly the company is already designing a late-stage PTSD trial while preparing providers for COMP360 rollout.
Clearmind (CMND) expands its AUD study to Tel Aviv, as Enveric (ENVB) reports its novel amylin-agonist antibody slashes food intake by 60% in obese mice.
Enveric (ENVB) wins USPTO nod for its non-hallucinogenic tryptamine patents, while Cybin (CYBN) gets a bullish $106 price target in new analyst coverage.
